Patents Assigned to Ortho-McNeil Pharamaceutical, Inc.
  • 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
    Patent number: 8501791
    Abstract: The present invention is directed to novel 1,2,4-thiadiazol-2-ium derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II diabetes, Syndrome X, diabetic retinopathy, spinal cord injury, nerve injury, acute neurodegenerative disorders, chronic neurodegenerative disorders, plexopathies, male erectile dysfunction, dry eyes, acne, dry skin, aged skin, seborrheic dermatitis, rosacea, excessive ear wax, meibomian gland disorder, pseudofolliculitis, yeast infections, dandruff, hidradenitis suppurativa, ocular rosacea and eccrine gland disorder.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: August 6, 2013
    Assignee: Ortho-McNeil Pharamaceutical, Inc.
    Inventors: Magdalena Eisinger, Louis J. Fitzpatrick, Daniel H. Lee, Kevin Pan, Carlos Plata-Salaman, Allen B. Reitz, Virginia L. Smith-Swintosky, Boyu Zhao
  • Isoindolyl and isoquinolinyl aroyl pyrrole compounds
    Patent number: 6492387
    Abstract: This invention is directed to isoindolyl and isoquinolinyl aroyl pyrrole compounds pharmaceutically useful as agents or modulators for the treatment of central nervous system disorders and methods for the treatment of central nervous system disorders.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: December 10, 2002
    Assignee: Ortho-McNeil Pharamaceutical, Inc.
    Inventors: John R. Carson, Philip M. Pitis